The ABPI Code of Practice has always included strict requirements for the certification of promotional and some non-promotional activities and materials.
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.